Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Health Catalyst, Inc.    HCAT

HEALTH CATALYST, INC.

(HCAT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HEALTH CATALYST, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

11/10/2020 | 04:10pm EST

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2020, Health Catalyst, Inc. (the Company) issued a press release relating to its financial results for the quarter ended September 30, 2020. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1.

The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

•President:

On November 10, 2020, the Company announced that J. Patrick Nelli, the Company's Chief Financial Officer, will step down as CFO and assume a newly-created role of President of the Company, both effective January 1, 2021.

•Chief Financial Officer: On November 10, 2020, the Company announced that Bryan Hunt, age 34, the Company's Senior Vice President of Financial Planning and Analysis, will assume the role of Chief Financial Officer of the Company, effective January 1, 2021. Mr. Hunt has served as the Company's Senior Vice President of Financial Planning and Analysis since 2019. Mr. Hunt has served in a variety of leadership roles in the Company's finance function and in its internal analytics function since joining the company in April of 2014. Prior to joining the Company, Mr. Hunt served as an investment banker at Deloitte Corporate Finance, from 2011 to 2014. Mr. Hunt began his career as an investment banker at Moelis & Company. Mr. Hunt brings more than 10 years of experience in finance and operations across various size companies to the CFO position. Mr. Hunt holds a Bachelor's degree in Accounting from Brigham Young University, where he graduated cum laude. In connection with his appointment, the Company expects to enter into an indemnification agreement with Mr. Hunt and expects Mr. Hunt will participate in its Executive Severance Plan, effective January 1, 2021.

•Chief Accounting Officer: On November 10, 2020, the Company announced that Jason Alger, age 37, the Company's Senior Vice President of Finance, will assume the role of Chief Accounting Officer of the Company, effective January 1, 2021. In this role, Mr. Alger will serve as the Company's principal accounting officer. Mr. Alger has served as the Company's Senior Vice President of Finance since September 2017, and as Controller since April 2013. Prior to joining the Company, Mr. Alger was at the public accounting firm, Ernst & Young LLP, in its assurance practice from August 2009 to April 2013. Mr. Alger is a certified public accountant and holds a Master of Accountancy degree from Brigham Young University. In connection with his appointment, the Company expects to enter into an indemnification agreement with Mr. Alger and expects Mr. Alger will participate in its Executive Severance Plan, effective January 1, 2021.

•Director Resignation: On November 9, 2020, the board of directors of the Company accepted Mike Dixon's resignation from the board, including his resignation from the nominating and corporate governance committee of the board, effective December 31, 2020. Mr. Dixon's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Except for the arrangements described in this Current Report on Form 8-K, there are no existing or currently proposed transactions to which the Company or any of its subsidiaries is a party and in which Messrs. Nelli, Hunt or Alger have a direct or indirect material interest. There are no family relationships between any of Messrs. Nelli, Hunt or Alger and any of the Company's directors or executive officers.

A copy of the press release announcing the appointments of Messrs. Nelli, Hunt and Alger is attached hereto as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.                                                   Description
                                     Health Catalyst, Inc. press release for quarterly financial
  99.1*                            results, dated November 10, 2020Health Catalyst, Inc. press release announcing appointment of
  99.2                             officers, dated November 10, 2020



* Furnished herewith.

© Edgar Online, source Glimpses

All news about HEALTH CATALYST, INC.
01/19BUSINESS RADIO X : Trudy Sullivan Interview
PU
01/18HEALTH CATALYST : Becker's Healthcare CEO + CFO Forum
PU
01/13HEALTH CATALYST : Named a Glassdoor Best Places to Work for the Fourth Time in S..
PU
01/13HEALTH CATALYST : Re-Certified as a Great Place to Work Company
PU
01/07HEALTH CATALYST : Data Bridge the Knowledge Gaps in the Fight Against COVID-19
PU
01/07TRANSFORMATION CAPITAL : Launches $500 Million Digital Health Fund to Support En..
PR
2020Health Catalyst to Participate in Upcoming Investor Conference
GL
2020HEALTH CATALYST : Utah Companies Recognized for Leadership, Training and Creativ..
PU
2020HEALTH CATALYST : As Pfizer Vaccine Gets Emergency Approval, Experts Say It's Ti..
PU
2020HEALTH CATALYST : Farhana Nakhooda COVID-19 Role of Data Interview (Channel News..
PU
More news
Financials (USD)
Sales 2020 188 M - -
Net income 2020 -91,8 M - -
Net cash 2020 96,9 M - -
P/E ratio 2020 -21,4x
Yield 2020 -
Capitalization 2 181 M 2 181 M -
EV / Sales 2020 11,1x
EV / Sales 2021 9,31x
Nbr of Employees 1 000
Free-Float 95,1%
Chart HEALTH CATALYST, INC.
Duration : Period :
Health Catalyst, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEALTH CATALYST, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 44,85 $
Last Close Price 51,33 $
Spread / Highest target -2,59%
Spread / Average Target -12,6%
Spread / Lowest Target -27,9%
EPS Revisions
Managers and Directors
NameTitle
Daniel D. Burton Chief Executive Officer & Director
Patrick J. Nelli President
Paul Horstmeier Chief Operating Officer
Bryan Hunt Chief Financial Officer
Holly Rimmasch Chief Clinical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HEALTH CATALYST, INC.17.92%2 181
THERMO FISHER SCIENTIFIC10.00%203 954
DANAHER CORPORATION7.16%169 098
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.12.25%89 689
INTUITIVE SURGICAL, INC.-9.05%87 471
ILLUMINA, INC.9.80%59 313